Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504238 · ClinicalTrials.gov registry record
Non-Invasive Monitoring Methods in Patients With Acute Brain Injury
A clinical trial of Brain Injury, Acute, sponsored by Boston Medical Center.
- Recruiting
- Registry status
- 720
- Enrollment target
- 1
- Study location
NCT06504238: Recruiting study of Brain Injury, Acute, sponsored by Boston Medical Center.
NCT06504238 is a study of Brain Injury, Acute that is actively recruiting participants, run by Boston Medical Center. The registered enrollment target is 720 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06504238, a study of Brain Injury, Acute, is actively recruiting participants, sponsored by Boston Medical Center.
- RECRUITING
- Registry status
- 720 participants
- Enrollment target
- 1
- Study location
Study Summary
Life-threatening mass effect (LTME) arises when brain swelling displaces or compresses crucial midline structures subsequent to acute brain injuries (ABIs) like traumatic brain injury (TBI), ischemic stroke (IS), and intraparenchymal hemorrhage (IPH), which can manifest rapidly within hours or more gradually over days. Despite advancements in surgical management, significant gaps in understanding persist regarding optimal monitoring and therapeutic approaches. The current standard for identifying LTME involves neurologic decline in conjunction with radiographic evidence or increased intracranial pressure (ICP) indicating space-occupying mass effect. However, in critically ill patients, reliance on subjective physical exam findings, such as decreased arousal, often leads to delayed recognition, occurring only after catastrophic shifts have already occurred. The goal of this study is to determine the association of non-invasive biomarkers with neurologic deterioration, and to determine whether non-invasive biomarker inclusion improves detection of outcome and decline. The investigators propose to use various non-invasive methods to monitor ICP as adjuncts in detecting deteriorating mass effect. These methods include quantitative pupillometry, radiographic data, laboratory data, and other bedside diagnostic tests available including electroencephalography (EEG), skull vibrations detected via brain4care device, optic nerve sheath diameter assessment (ONSD), and ultrasound-guided eyeball compression. Some of these methods will be measured \*only\* for the purposes of the research study (such as skull vibrations via brain4care). Other measurements, such as quantitative pupillometry, will represent additional measurements beyond those already being collected for clinical care. This research study is necessary to understand the association of these non-invasive biomarkers with neurological decline and outcomes while considering potential confounding factors.
Primary Outcome
Neurologic deterioration will be assessed as a dichotomous variable (yes/no) defined as a negative change in any of the following: level of consciousness, agaze, arm motor function, leg motor function, or language. The participants' medical chart will be reviewed for documentation of persistent change.
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2024-09-26 |
| Est. Completion | 2030-09 |
What NCT06504238 shows while recruiting
NCT06504238 is an observational study that tracks outcomes without assigning an intervention. The registered 720 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Brain Injury, Acute appearing as the primary indexed condition, and to 0 interventions.
NCT06504238 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06504238 about?
NCT06504238 is a clinical study titled "Non-Invasive Monitoring Methods in Patients With Acute Brain Injury". Life-threatening mass effect (LTME) arises when brain swelling displaces or compresses crucial midline structures subsequent to acute brain injuries (ABIs) like traumatic brain injury (TBI), ischemic stroke (IS), and intraparenchymal hemorrhage (IPH), which can manifest rapidly within hours or more ...
What is the current status of trial NCT06504238?
This trial is currently recruiting. The enrollment target is 720 participants. The study started on 2024-09-26. Estimated completion is 2030-09.
What conditions does trial NCT06504238 study?
This clinical trial studies the following conditions: Brain Injury, Acute.
Who is sponsoring clinical trial NCT06504238?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504238 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
- NCT05466214 · 720 participants · NA
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI